The global dual chamber injectors and syringes market is expected to witness strong growth during the forecast period between 2021 and 2031.
Dual chamber injectors and syringes are medical instruments used to store pharmaceutical drugs and unstable biological substances such as blood, tissue, and serum for long periods.
These devices are used to preserve the sterility of drugs before injection in a bid to prevent drug loss. Dual chamber injectors and syringes provide consumers the convenience to administer sensitive drugs.
The COVID-19 pandemic adversely affected the global dual chamber injectors and syringes market owing to disruptions in the demand and supply of products.
Expanding operations in future? To get the perfect launch ask for a custom report
Rising need to store biological substances and lyophilized drugs at cold temperatures before they are used is the key growth driver for the global dual chamber injectors and syringes market.
Innovations to existing products could help fuel product demand and propel the overall dual chamber injectors and syringes market, in the coming years.
Growing need to reconstitute lyophilized drugs at the point of administration is expected to drive the demand for dual chamber injectors and syringes, in the years ahead.
Government initiatives and measures, promoting the use of dual chamber injectors and syringes at different healthcare infrastructure facilities such as hospitals and clinics are expected the drive the growth in the overall market, in future.
The plastic type of dual chamber injectors and syringes is expected to make the largest contribution to the overall market in the coming years owing to the disposable nature of the product, resulting in increased demand.
The online retail distribution channel is anticipated to contribute the most to the dual chamber injectors and syringes market owing to increasing number of consumers preferring to purchase syringe products over the internet, as compared to physical retail stores.
The global dual chamber injectors and syringes market is still at a developing stage and comprises very few players. These players are expected to engage in different growth strategies such as new product launches, in a bid to remain competitive in the overall market.
Leading players could also collaborate with the lesser-known players in the global dual chamber injectors and syringes market in a bid to expand their market presence and improve their revenue share.
R&D undertakings could be a key growth strategy for the prominent players in the overall market, in the upcoming years.
A few players in the global dual chamber injectors and syringes market include Amylin Pharmaceuticals LLC, Pfizer, Becton Dickinson, Vetter Pharma, Hospira, and Ypsomed.
The vaccines developed by Pfizer to tackle the COVID-19 pandemic found acceptance in the leading global economies.
Request a sample to get extensive insights into the Dual Chamber Injectors and Syringes Market
North America is expected to be the dominant region in the dual chamber injectors and syringes market owing to the presence of several leading players in countries such as the U.S and Canada.
Europe is expected to provide profitable growth opportunities for the overall market owing to the rising need to store lyophilized drugs and control the biological stability of substances in countries such as UK and Germany.
Asia Pacific is expected to witness moderate growth in the dual chamber injectors and syringes market due to the developing healthcare infrastructure facilities in countries such as India.
Well-established players could establish R&D centers in countries such as India, owing to the ease of availability of key resources such as land and labor.
Other regions of the world such as Latin America and Middle East and Africa are expected to witness moderate growth in the overall market, in the coming years owing to the lack of awareness of the product in the countries, part of both regions.
Interested in this report?
Get a FREE Brochure now!
*Get Brochure (PDF) sent to your email within minutes
Get a free copy if the report you purchased is updated within 90 days